The FDA has granted 510(k) clearance to Selux Diagnostics for its next-generation phenotyping (NGP) system, a rapid antibiotic susceptibility testing platform for gram-positive bacteria.

The NGP system has the potential to decrease overreliance on broad-spectrum antibiotics since results provide specific susceptibility, enabling clinicians to prescribe a targeted antibiotic for gram-positive bacteria such as Staphylococcus aureus.

The FDA is currently reviewing the company’s NGP system for assessing the antibiotic susceptibility of gram-negative bacteria.